NCT05755035: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases |
|
|
| Recruiting | 2/3 | 75 | Europe, US, RoW | TAK-881, Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20)., HYQVIA, Immune Globulin Infusion (Human), 10% Solution with rHuPH20. | Takeda, Takeda Development Center Americas, Inc. | Primary Immunodeficiency Diseases (PID) | 02/26 | 09/26 | | |
ABCVILD, NCT04925375: Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease |
|
|
| Recruiting | 2 | 38 | US | Abatacept, Orencia, Placebo | Children's Hospital Medical Center, Cincinnati, Bristol-Myers Squibb | Interstitial Lung Disease, Common Variable Immunodeficiency | 07/25 | 07/25 | | |
NCT03878069: Registry Study of Revcovi Treatment in Patients With ADA-SCID |
|
|
| Completed | N/A | 32 | US | elapegademase-lvlr, Revcovi | Chiesi Farmaceutici S.p.A. | Adenosine Deaminase Severe Combined Immunodeficiency | 01/23 | 01/23 | | |
